Скачать или смотреть Phase III trial of rusfertide in patients with polycythemia vera

Phase II studies have demonstrated that rusfertide, a hepcidin mimetic, is very well tolerated and effectively achieves hematocrit control in patients with polycythemia vera (PV). Treatment with rusfertide essentially eliminated phlebotomy requirements, as well as improving symptomatic iron deficiency: an unaddressed clinical challenge in patients with PV. Srdan Verstovsek, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares the details of the planned Phase III investigation, following the promising results demonstrated to date. The multicenter, randomized, blinded trial will compare the safety and efficacy of rusfertide versus placebo as an add on to current PV therapy. The 32-week study period will be followed by an open-label treatment phase and a long-term extension. Dr Verstovsek gives his thoughts on the promise of rusfertide as a new therapy in the near future. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.